Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: John Carragher who wrote (386)	10/30/1998 11:59:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 642

Eli Lilly to Expand Sales Force for Evista Osteoporosis Drug Bloomberg News October 30, 1998, 11:20 a.m. ET Eli Lilly to Expand Sales Force for Evista Osteoporosis Drug Indianapolis, Oct. 30 (Bloomberg) -- Eli Lilly & Co. said it's boosting its sales force for its osteoporosis drug Evista as the world's 10th-largest drugmaker looks to increase sales of its new drugs. Lilly is reorganizing its sales force, not adding new staff, the company said. The larger Evista sales force will allow Lilly, beginning in January, to market the drug beyond obstetricians and gynecologists to primary-care providers and other doctors, the company said. Evista, introduced in January, is used to prevent thinning of bones, a condition known as osteoporosis, which largely affects older women. Lilly hopes to increase sales of Evista and other drugs such as Zyprexa to offset the expiration of its patent on Prozac, the world's best-selling antidepressant, early in the next decade. Evista had third-quarter sales of $33.2 million in the third quarter, compared with Prozac's $793 million in sales for the same period. Indianapolis-based Lilly is testing whether Evista can be used to prevent breast cancer and heart disease. Lilly won approval to sell Evista in the European Union in the third quarter. Lilly fell 3/16 to 80 1/16 in late morning trading. --Jeannine DeFoe in the Princeton newsroom (609) 279-4096 /jjs